On January 23, 2018 GT Biopharma Inc. (OTCQB: GTBP and Euronext Paris: GTBP.PA) reported that it has entered into definitive agreements for a private placement of convertible notes and warrants for gross proceeds of $7,055,000 (Press release, GT Biopharma , JAN 23, 2018, View Source [SID1234539535]). The company intends to use the proceeds from the financing to advance its immuno-oncology programs, which are based on the company’s proprietary Tri and Tetra-specific Natural Killer Cell Engagers (TriKEs and TetraKEs) and bispecific antibody-drug conjugate (ADC) platforms, neurology (CNS) pipeline progress, and for general corporate purposes.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Oppenheimer & Co. Inc. acted as the sole placement agent for the offering.

The convertible notes are unsecured, have a face amount of $7,760,508, a 0% coupon, an initial conversion price of $4.58, subject to adjustment, and are due July 2018. Investors also received warrants to purchase approximately 1,694,440 shares of GT Biopharma common stock at an initial exercise price of $4.58 per share, subject to adjustment.

Roth Capital Partners also acted as a financial advisor to GT Biopharma for this transaction.

On January 23, 2018 Genmab A/S (Nasdaq Copenhagen: GEN) reported that worldwide net sales of DARZALEX (daratumumab) as reported by Johnson & Johnson were USD 1,242 million in 2017. Net sales were USD 884 million in the U.S. and net sales in the rest of the world were USD 358 million (Press release, Genmab, JAN 23, 2018, View Source [SID1234523485]). Genmab receives royalties on the worldwide net sales of DARZALEX under the exclusive worldwide license to Janssen Biotech, Inc. to develop, manufacture and commercialize DARZALEX.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

DARZALEX was approved in the U.S. in November 2015, in Europe in May 2016 and in Japan in September 2017. Worldwide net sales of DARZALEX in 2016 were USD 572 million, resulting in royalty income of DKK 458 million to Genmab.

On January 23, 2018 Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology Company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, reported that an overview of the Company’s business strategy and commercial and development-stage programs will be given at the Noble Capital Markets’ Fourteenth Annual Investor Conference being held at the W Hotel, Fort Lauderdale, Florida (Press release, Spectrum Pharmaceuticals, JAN 23, 2018, http://investor.sppirx.com/news-releases/news-release-details/spectrum-pharmaceuticals-present-corporate-update-noble-capital [SID1234523570]). The Company presentation is on Tuesday, January 30, 2018, at 1:30 PM EST.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A high-definition, video webcast of the presentation will be available the following day on the Company’s web site at www.sppirx.com under Investor Relations.

On January 23, 2018 Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a company working to improve patient lives by providing high quality biologics manufacturing services to biotechnology and pharmaceutical companies, reported that its president and chief executive officer, Roger J. Lias, Ph.D., will deliver a corporate presentation at NobleCon14 – Noble Financial Capital Markets’ Fourteenth Annual Investor Conference, being held January 29-30, 2018 at the W Fort Lauderdale Beach Hotel in Fort Lauderdale, Florida (Press release, Peregrine Pharmaceuticals, JAN 23, 2018, View Source [SID1234523566]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details of this presentation are as follows:

NobleCon14
Time/Date: 11:30 a.m. ET on Monday, January 29, 2018
Location: W Fort Lauderdale Beach Hotel
Room: Studio 1
Avid’s presentation at NobleCon14 will be webcast live and available for replay at: View Source

On January 24, 2018 Novartis CEO Joe Jimenez reported fourth quarter and full year 2017 results (Press release, Novartis, JAN 23, 2018, View Source [SID1234523565]). In his remarks Jimenez said: "It was a landmark year for innovation resulting in a rich late-stage pipeline. With several key launches on the horizon and our new operating model in place, Novartis is poised for sustainable growth."

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Vas Narasimhan, designated CEO from February 1, commented: "I want to thank Joe and the Board for their leadership and guidance as I transition to my new role. I feel privileged to lead Novartis at this exciting time."